Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 17/20 | 0.41 |
| ▸ | AKT2 | P31751 | 8/20 | 0.39 |
| ▸ | AKT3 | Q9Y243 | 2/20 | 0.39 |
| ▸ | FECH | P22830 | 1/20 | 0.39 |
| ▸ | TACR3 | P29371 | 1/20 | 0.35 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1352537 | 0.92 | AKT1 (0.41) | AKT1AKT2AKT3FECH | |
| SCHEMBL1351858 | 0.91 | AKT1 (0.40) | AKT1AKT2AKT3FECHTACR3 | |
| SCHEMBL1351794 | 0.90 | AKT1 (0.40) | AKT1AKT2AKT3FECH | |
| SCHEMBL1352428 | 0.89 | AKT1 (0.39) | AKT1AKT2AKT3FECHTACR3 | |
| SCHEMBL4299454 | 0.89 | AKT1 (0.38) | AKT1AKT2AKT3FECH | |
| SCHEMBL1351777 | 0.89 | AKT1 (0.41) | AKT1AKT2AKT3FECHTACR3 | |
| SCHEMBL1352553 | 0.87 | DHODH (0.39) | AKT1AKT2AKT3FECH | |
| SCHEMBL2027954 | 0.87 | AKT1 (0.39) | AKT1AKT2AKT3FECH | |
| SCHEMBL1352098 | 0.85 | AKT1 (0.46) | AKT1AKT2AKT3FECHSLC22A12 | |
| SCHEMBL1352355 | 0.85 | AKT1 (0.38) | AKT1AKT2AKT3FECH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110288090-A1 | Inhibitors of AKT Activity | MERCK SHARP & DOHME CORP. | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288090-A1 | Inhibitors of AKT Activity | PIK3CD, PIK3CA, PIK3CG | AKT1 9/4885AKT2 5/4885AKT3 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.